Mark Mal­lon wraps a short stint as CEO of Iron­wood, jump­ing out to pur­sue 'mul­ti­ple pas­sion­s' in the wake of set­backs

Mark Mal­lon built his ca­reer over a 24-year stretch at As­traZeneca. But he man­aged less than 2 years as CEO of Iron­wood.

Iron­wood an­nounced Mon­day af­ter­noon that Mal­lon is step­ping down, quot­ing him as en­thused about the chance to sat­is­fy “mul­ti­ple pas­sions” as he head­ed off in pur­suit of a new lead­er­ship post. The biotech’s stock was up 13% ahead of the bell Tues­day.

Pres­i­dent Tom Mc­Court was bumped to the in­ter­im CEO role dur­ing the re­cruit­ment phase for the next CEO and the board chair, Julie McHugh, will help steer the com­pa­ny as ex­ec­u­tive chair­man.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER